-
EP3603661
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3603661
| EP3603661 - RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 14.10.2022 Database last updated on 05.07.2024 | |
| Former | Request for examination was made Status updated on 03.01.2020 | Most recent event Tooltip | 11.06.2024 | New entry: Additional fee for renewal fee: payment of fee | 11.06.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states CureVac SE Friedrich-Miescher-Straße 15 72076 Tübingen / DE | [2023/01] |
| Former [2021/10] | For all designated states CureVac AG Friedrich-Miescher-Straße 15 72076 Tübingen / DE | ||
| Former [2020/06] | For all designated states CureVac AG Paul-Ehrlich-Str. 15 72076 Tübingen / DE | Inventor(s) | 01 /
Fotin-Mleczek, Mariola c/o IP DEPARTMENT CureVac AG Friedrich-Miescher-Str. 15 72706 Tübingen / DE | 02 /
Kowalczyk, Aleksandra c/o IP DEPARTMENT CureVac AG Friedrich-Miescher-Str. 15 72706 Tübingen / DE | 03 /
Heidenreich, Regina c/o IP DEPARTMENT CureVac AG Friedrich-Miescher-Str. 15 72706 Tübingen / DE | 04 /
Baumhof, Patrick c/o IP DEPARTMENT CureVac AG Friedrich-Miescher-Str. 15 72706 Tübingen / DE | 05 /
Probst, Jochen c/o IP DEPARTMENT CureVac AG Friedrich-Miescher-Str. 15 72706 Tübingen / DE | 06 /
Kallen, Karl-Josef c/o IP DEPARTMENT CureVac AG Friedrich-Miescher-Str. 15 72706 Tübingen / DE | [2020/45] |
| Former [2020/06] | 01 /
Fotin-Mleczek, Mariola c/o IP DEPARTMENT CureVac AG Paul Ehrlich Str. 15 72076 Tübingen / DE | ||
| 02 /
Kowalczyk, Aleksandra c/o IP DEPARTMENT CureVac AG Paul Ehrlich Str. 15 72076 Tübingen / DE | |||
| 03 /
Heidenreich, Regina c/o IP DEPARTMENT CureVac AG Paul Ehrlich Str. 15 72076 Tübingen / DE | |||
| 04 /
Baumhof, Patrick c/o IP DEPARTMENT CureVac AG Paul Ehrlich Str. 15 72076 Tübingen / DE | |||
| 05 /
Probst, Jochen c/o IP DEPARTMENT CureVac AG Paul Ehrlich Str. 15 72076 Tübingen / DE | |||
| 06 /
Kallen, Karl-Josef c/o IP DEPARTMENT CureVac AG Paul Ehrlich Str. 15 72076 Tübingen / DE | Representative(s) | Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstraße 22 80538 München / DE | [2020/06] | Application number, filing date | 19181044.9 | 22.04.2016 | [2020/06] | Priority number, date | EP20150001191 | 22.04.2015 Original published format: EP 15001191 | [2020/06] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP3603661 | Date: | 05.02.2020 | Language: | EN | [2020/06] | Type: | A3 Search report | No.: | EP3603661 | Date: | 01.04.2020 | Language: | EN | [2020/14] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 28.02.2020 | Classification | IPC: | A61K38/19, C07K14/52, A61K38/20, A61K39/00, C12N15/113, C12N15/117, A61P35/00 | [2020/06] | CPC: |
A61K31/7105 (EP,RU,US);
A61K48/005 (CN,KR,US);
A61K31/7088 (CN);
A61K31/713 (EP,US);
A61K38/177 (EP,CN,KR,US);
A61K38/1774 (EP,CN,US);
A61K38/19 (EP,CN,KR,RU,US);
A61K38/191 (US);
A61K38/20 (CN);
A61K38/208 (EP,KR,US);
A61K39/0011 (CN);
A61K39/12 (EP,US);
A61K39/145 (US);
A61K39/39 (EP,US);
A61K39/3955 (EP,KR,US);
A61K39/39558 (CN,KR,US);
A61K45/06 (CN,KR,US);
A61K48/0025 (US);
A61K48/0041 (KR,US);
A61K9/0019 (CN,US);
A61P35/00 (EP);
A61P43/00 (EP);
C07K16/2818 (EP,KR,US);
C07K16/2878 (US);
C07K16/2896 (EP,US);
C07K16/30 (US);
C07K16/34 (EP,US);
C12N15/113 (RU);
C12N15/117 (KR,US);
C12N7/00 (US);
C12Q1/6806 (RU);
A61K2039/53 (EP,CN,US);
A61K2039/54 (EP,CN,US);
A61K2039/55511 (EP,CN,US);
A61K2039/55522 (EP,CN,US);
A61K2039/55538 (EP,CN,US);
A61K2039/55561 (EP,US);
A61K2039/585 (EP,CN,US);
A61K2300/00 (KR);
C07K2317/75 (US);
C07K2317/76 (US);
C12N2310/17 (US);
C12N2320/30 (US);
C12N2760/16034 (US);
C12N2760/16134 (EP,US);
Y02A50/30 (EP,US)
(-)
| C-Set: |
A61K31/7088, A61K2300/00 (CN);
A61K38/1774, A61K2300/00 (CN);
A61K38/177, A61K2300/00 (CN);
A61K38/19, A61K2300/00 (CN);
A61K38/20, A61K2300/00 (CN);
A61K39/0011, A61K2300/00 (CN); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/06] | Title | German: | RNA-HALTIGE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON TUMORERKRANKUNGEN | [2020/06] | English: | RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES | [2020/06] | French: | COMPOSITION CONTENANT UN ARN POUR LE TRAITEMENT DE MALADIES TUMORALES | [2020/06] | Examination procedure | 19.06.2019 | Examination requested [2020/06] | 01.10.2020 | Amendment by applicant (claims and/or description) | 14.10.2022 | Despatch of a communication from the examining division (Time limit: M06) | 19.05.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 19.07.2023 | Reply to a communication from the examining division | Parent application(s) Tooltip | EP16166757.1 / EP3173092 | EP17196250.9 / EP3326641 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 19.07.2023 | Request for further processing filed | 19.07.2023 | Full payment received (date of receipt of payment) Request granted | 27.07.2023 | Decision despatched | Fees paid | Renewal fee | 19.06.2019 | Renewal fee patent year 03 | 19.06.2019 | Renewal fee patent year 04 | 31.03.2020 | Renewal fee patent year 05 | 19.04.2021 | Renewal fee patent year 06 | 20.04.2022 | Renewal fee patent year 07 | 17.04.2023 | Renewal fee patent year 08 | 10.06.2024 | Renewal fee patent year 09 | Penalty fee | Additional fee for renewal fee | 30.04.2024 | 09 M06 Fee paid on 10.06.2024 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XYI]WO0162274 (INST CIENTIFICO TECNOL NAVARRA [ES], et al) [X] 1-8 * abstract * * claim - * [Y] 1-10 [I] 1-10; | [XDYI]WO02098443 (VON DER MUELBE FLORIAN [DE], et al) [XD] 1-10 * abstract * * example -; claim - * * page 14, line 8 - page 17, line 2 * [Y] 1-10 [I] 1-10; | [XYI]US2003118564 (MOLLING KARIN [CH], et al) [X] 1-10 * abstract * * page 1, paragraph 0001 - page 4, paragraph 0038 * * examples 1-6 * * claim - * [Y] 1-10[I] 1-10; | [XYI]WO2006024518 (CUREVAC GMBH [DE], et al) [X] 1-10 * abstract * [Y] 1-10 [I] 1-10; | [Y]EP2623121 (BAYER INNOVATION GMBH [DE], et al) [Y] 1-10 * abstract * * sequence 106 * * example - * * claim - * * paragraph [0244] *; | [IDY]WO2014127917 (CUREVAC GMBH [DE]) [ID] 1-10 * abstract * * claim - * * example - * [Y] 1-10; | [XYI] - FOTIN-MLECZEK M ET AL, "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, vol. 14, no. 6, doi:10.1002/JGM.2605, ISSN 1099-498X, (20120601), pages 428 - 439, (20120627), XP002716014 [X] 1-10 * abstract * * page 428, paragraph 1 - page 437, column r, paragraph 2 * [Y] 1-10 [I] 1-10 DOI: http://dx.doi.org/10.1002/jgm.2605 | [XYI] - ELIAS J SAYOUR ET AL, "Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, (20150421), vol. 3, no. 1, doi:10.1186/S40425-015-0058-0, ISSN 2051-1426, page 13, XP021216038 [X] 1-6,9 * abstract * * page 1, column l, paragraph 1 - page 5, column l, paragraph 2 * [Y] 1-10 [I] 1-10 DOI: http://dx.doi.org/10.1186/s40425-015-0058-0 | [XYI] - SCHIRRMACHER V ET AL, "Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine", GENE THERAPY, NATURE PUBLISHING GROUP, GB, (20000701), vol. 7, no. 13, doi:10.1038/SJ.GT.3301220, ISSN 0969-7128, pages 1137 - 1147, XP002359468 [X] 1-8 * abstract * * page 1137, column l, paragraph 1 - page 1144, column r, paragraph 2 * [Y] 1-10 [I] 1-10 DOI: http://dx.doi.org/10.1038/sj.gt.3301220 | [XYI] - BONTKES H J ET AL, "Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 127, no. 3, doi:10.1016/J.CLIM.2008.02.001, ISSN 1521-6616, (20080601), pages 375 - 384, (20080321), XP022673824 [X] 1-8 * abstract * * page 375, column l, paragraph 1 - page 383, column r, paragraph 2 * [Y] 1-10 [I] 1-10 DOI: http://dx.doi.org/10.1016/j.clim.2008.02.001 | [IY] - S TUGUES ET AL, "New insights into IL-12-mediated tumor suppression", CELL DEATH AND DIFFERENTIATION., GB, (20140905), vol. 22, no. 2, doi:10.1038/cdd.2014.134, ISSN 1350-9047, pages 237 - 246, XP055285716 [I] 1-10 * abstract * * page 237, column l, paragraph 1 - page 243, column r, paragraph 1 * * table 1 * [Y] 1-10 DOI: http://dx.doi.org/10.1038/cdd.2014.134 | [Y] - SALLY M. AMOS ET AL, "Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, (20110501), vol. 60, no. 5, doi:10.1007/s00262-011-0984-8, ISSN 0340-7004, pages 671 - 683, XP055285721 [Y] 1-10 * abstract * * page 671, column r, paragraph 1 - page 681, column l, paragraph 3 * DOI: http://dx.doi.org/10.1007/s00262-011-0984-8 | [Y] - AMMI RACHID ET AL, "Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs", PHARMACOLOGY AND THERAPEUTICS, (20141014), vol. 146, doi:10.1016/J.PHARMTHERA.2014.09.010, ISSN 0163-7258, pages 120 - 131, XP029132937 [Y] 1-10 * abstract * * page 120, column l, paragraph 1 - page 129, column l, paragraph 4 * DOI: http://dx.doi.org/10.1016/j.pharmthera.2014.09.010 | by applicant | WO9512673 | WO9521251 | WO9521915 | EP1083232 | WO02098443 | WO03051401 | WO03086280 | WO2006008154 | US7074596 | WO2008016473 | WO2008077592 | WO2008083949 | WO2008157688 | WO2009030481 | WO2009149253 | WO2010037539 | WO2011015347 | WO2011026641 | WO2012013326 | WO2012019780 | WO2012113513 | WO2012116811 | WO2013059475 | WO2013143700 | WO2014127917 | WO2014189805 | - STEPINSKI et al., RNA, (20010000), vol. 7, no. 10, pages 1486 - 95 | - KORE et al., Bioorg. Med. Chem., (20130000), vol. 21, no. 15, pages 4570 - 4 | - KARLIN et al., PNAS USA, (19930000), vol. 90, pages 5873 - 5877 | - ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402 | - GEALL et al., Semin. Immunol., (20130000), vol. 25, no. 2, pages 152 - 159 | - BRUNELLE et al., Methods Enzymol., (20130000), vol. 530, pages 101 - 14 | - BRINCKER, Crit. Rev. Oncol. Hematol., (19930000), vol. 15, no. 2, pages 91 - 8 | - CELIKOGLU et al., Cancer Therapy, (20080000), vol. 6, pages 545 - 552 | - GRIFFITH et al., Annu. Rev. Immunol., (20140000), vol. 32, pages 659 - 702 | - ARDIANI et al., Curr. Gene Ther., (20120000), vol. 12, no. 2, pages 77 - 91 | - MOOLTEN, Cancer Res., (19860000), vol. 46, no. 10, pages 5276 - 81 | - KROEMER, G. et al., "Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009", Cell Death & Differentiation, (20090000), vol. 16.1, doi:doi:10.1038/cdd.2008.150, pages 3 - 11, XP055348325 DOI: http://dx.doi.org/10.1038/cdd.2008.150 | - ELMORE, Toxicol Pathol., (20070000), vol. 35, no. 4, pages 495 - 516 | - ASHKENAZI, Nat. Rev. Drug Discov., (20080000), vol. 7, no. 12, pages 1001 - 12 | - FOLKMAN, N. Engl. J. Med., (19720000), vol. 285, no. 21, pages 1182 - 6 | - HANAHANFOLKMAN, Cell, (19960000), vol. 86, no. 3, pages 353 - 64 | - PERSANO et al., Mol. Aspects Med., (20070000), vol. 28, no. 1, pages 87 - 114 | - GRANER MWLILLEHEI KOKATSANIS E, "Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines", Front Oncol., (20150106), vol. 4, page 379 | - THAKUR RMISHRA DP, "Pharmacological modulation of beta-catenin and its applications in cancer therapy", J Cell Mol Med., (20130400), vol. 17, no. 4, doi:doi:10.1111/jcmm.12033, pages 449 - 56, XP055330302 DOI: http://dx.doi.org/10.1111/jcmm.12033 | - WOO SRCORRALES LGAJEWSKI TF, "The STING pathway and the T cell-inflamed tumor microenvironment", Trends Immunol., (20150307), vol. 1471-4906, no. 15, pages 00019 - 8 | - DUBENSKY TW JRKANNE DBLEONG ML, "Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants", Ther Adv Vaccines, (20131100), vol. 1, no. 4, doi:doi:10.1177/2051013613501988, pages 131 - 43, XP055177403 DOI: http://dx.doi.org/10.1177/2051013613501988 | - BOUR-JORDAN et al., Immunol Rev., (20110000), vol. 241, no. 1, pages 180 - 205 | - WEINBERG et al., J. Immunother., (20060000), vol. 29, no. 6, pages 575 - 585 | - WEBER, J., Semin. Oncol., (20100000), vol. 37, no. 5, pages 430 - 9 | - BRAHMER et al., J Clin Oncol., (20100000), vol. 28, no. 19, pages 3167 - 75 | - BERGER et al., Clin Cancer Res., (20080000), vol. 14, no. 10, pages 3044 - 51 | - BRAHMER et al., N Engl J Med., (20120000), vol. 366, no. 26, pages 2455 - 65 | - PRENDERGAST GCSMITH CTHOMAS SMANDIK-NAYAK LLAURY-KLEINTOP LMETZ RMULLER AJ, "Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer", Cancer Immunol. Immunother., (20140700), vol. 63, no. 7, doi:doi:10.1007/s00262-014-1549-4, pages 721 - 35, XP055411380 DOI: http://dx.doi.org/10.1007/s00262-014-1549-4 | - AKASHI, Curr. Opin. Genet. Dev., (20010000), vol. 11, no. 6, pages 660 - 666 | - CAPUT et al., Proc. Natl. Acad. Sci. USA, (19860000), vol. 83, pages 1670 - 1674 | - BINDER et al., EMBO J., (19940000), vol. 13, pages 1969 - 1980 | - "GenBank", Database accession no. NM_000477.5 | - LAI et al., Development, (19950000), vol. 121, pages 2349 - 2360 | - MEYLAN, E.TSCHOPP, J., "Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses", Mol. Cell, (20060000), vol. 22, doi:doi:10.1016/j.molcel.2006.05.012, pages 561 - 569, XP055512593 DOI: http://dx.doi.org/10.1016/j.molcel.2006.05.012 | - HEMMI H et al., Nature, (20000000), vol. 408, pages 740 - 5 | - BAUER S et al., Proc NatlAcadSci USA, (20010000), vol. 98, pages 9237 - 42 | - MEYLAN, E.J. TSCHOPP et al., Nature, (20060000), vol. 442, no. 7098, pages 39 - 44 | - Front Pharmacol., (20151201), vol. 6, page 286 | - Int J Nanomedicine, (20140000), vol. 9, pages 1833 - 1843 | - Adv Drug Deliv Rev., (20140200), vol. 66, pages 110 - 116 |